An outbreak of SARS-CoV-2 has led to a global pandemic affecting virtually every country. As of August 31, 2020, globally, there have been approximately 25,500,000 confirmed cases and 850,000 deaths; in the United States (50 states plus District of Columbia), there have been more than 6,000,000 confirmed cases and 183,000 deaths. We propose a Bayesian mixture model to predict and monitor COVID-19 mortality across the United States. The model captures skewed unimodal (prolonged recovery) or multimodal (multiple surges) curves. The results show that across all states, the first peak dates of mortality varied between April 4, 2020 for Alaska and June 18, 2020 for Arkansas. As of August 31, 2020, 31 states had a clear bimodal curve showing a strong second surge. The peak date for a second surge ranged from July 1, 2020 for Virginia to September 12, 2020 for Hawaii. The first peak for the United States occurred about April 16, 2020-dominated by New York and New Jersey-and a second peak on August 6, 2020-dominated by California, Texas, and Florida. Reliable models for predicting the COVID-19 pandemic are essential to informing resource allocation and intervention strategies. A Bayesian mixture model was able to more accurately predict the shape of the mortality curves across the United States than other models, including the timing of multiple peaks. However, given the dynamic nature of the pandemic, it is important that the results be updated regularly to identify and better monitor future waves, and characterize the epidemiology of the pandemic.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8045639 | PMC |
http://dx.doi.org/10.4269/ajtmh.20-1147 | DOI Listing |
Alzheimers Dement
December 2024
Karolinska Institute, Stockholm, Södermanland and Uppland, Sweden.
Background: Novel anti-amyloid therapies (AAT) for Alzheimer's Disease (AD) have recently been approved in the United States, Japan and China, and are under regulatory review in Europe. Questions remain regarding the long-term effectiveness and value of these drugs when used in routine clinical practice. Data from follow-up studies will be important to inform their optimal use, including criteria for treatment initiation, monitoring strategies, stopping rules, pricing and reimbursement considerations.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
ADEL Institute of Science & Technology (AIST), ADEL, Inc., Seoul, Korea, Republic of (South).
Background: The spatiotemporal pattern of the spread of pathologically modified tau through brain regions in Alzheimer's disease (AD) can be explained by prion-like cell-to-cell seeding and propagation of misfolded tau aggregates. Hence, to develop targeted therapeutic antibodies, it is important to identify the seeding- and propagation-competent tau species. The hexapeptide VQIINK of tau is a critical region for tau aggregation, and K280 is acetylated in various tauopathies including AD.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Center for Health + Technology, University of Rochester Medical Center, Rochester, NY, USA.
Background: In preparation for therapeutic trails involving patients with Alzheimer's disease (AD) and mild cognitive impairment (MCI), there is a need for valid, disease-specific caregiver-reported outcome (CRO) measures capable of tracking symptomatic burden in response to therapy over time. CROs are useful tools in clinical trials for individuals with AD, MCI, and dementia who are unable to self-report. In addition, CROs are accepted by the United States Food and Drug Administration to support regulatory claims.
View Article and Find Full Text PDFJ Phys Chem Lett
January 2025
National High Magnetic Field Laboratory, Florida State University, 1800 E. Paul Dirac Dr, Tallahassee, Florida 32310, United States.
The contribution of protons in or near biradical polarizing agents in Dynamic Nuclear Polarization (DNP) has recently been under scrutiny. Results from selective deuteration and simulations have previously suggested that the role of protons in the biradical molecule depends on the strength of the electron-electron coupling. Here we use the cross effect DNP mechanism to identify and acquire H solid-state NMR spectra of the protons that contribute to propagation of the hyperpolarization, via an experimental approach dubbed Nuclear-Nuclear Double Resonance (NUDOR).
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Department of Biomedical Engineering, McGill University, Montreal, QC, Canada.
Background: Randomized placebo-controlled trials (RCTs) are the gold standard to evaluate efficacy of new drug treatments for Alzheimer's disease. For example, the United States FDA approved the brain amyloid-targeting drug lecanemab following CLARITY AD, Biogen and Eisai's Phase 3 RCT. However, recruiting enough participants for a high-powered and demographically representative trial is difficult and expensive.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!